1790s

1790s

1800s

1800s

1810s

1810s

1820s

1820s

1830s

1830s

1840s

1840s

1850s

1850s

1860s

1860s

1870s

1870s

1880s

1880s

1890s

1890s

1900s

1900s

1910s

1910s

1920s

1920s

1930s

1930s

1940s

1940s

1950s

1950s

1960s

1960s

1970s

1970s

1980s

1980s

1990s

1990s

2000s

2000s

2010s

2010s

Timelines: 1979

Prev : Next Molecular Genetics, Inc.


Biotechnology for animal health

Molecular Genetics, Inc. is established in November, in the Minneapolis suburb of Minnetonka. The founders are Franklin Pass, an M.D. in the Department of Dermatology at the University of Minnesota Medical School, and Tony Faras, Ph.D., a virologist in the Department of Microbiology. The company intends to employ hybridoma and recombinant DNA technologies to develop vaccines and antitoxins in order to improve animal health. Commercial prospects are bright for effective new products in animal health – the markets are massive. In the U.S., 10-15% of livestock born in a given year succumb to infectious diseases. The company also plans to use rDNA techniques to design novel plant species with altered growth patterns and improved nutritional value.

In 1990, the firm shifts its focus from veterinary to human pharmaceuticals, and changes its name to MGI Pharma. In 2008, in $3.9 billion merger agreement, MGI became a wholly-owned subsidiary of Easai Corporation of North America. The company independently markets three drugs in the U.S. – Aloxi® (palonosetron hydrochloride), a 5-HT3 receptor antagonist indicated for chemotherapy-related nausea, Dacogen® (decitabine), an anti-cancer nucleoside analogue, and Gliadel® , an implantable, biodegradable, carmustine-based wafer used to treat malignant gliomas (brain cancers).

You have clicked on a link that will take you to another website. Click here to continue and leave the Life Sciences Foundation website.
Close